Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Beijing Biostar Pharmaceuticals Co 3-Year ROIIC %?
Beijing Biostar Pharmaceuticals CoHKSE:02563 9 3-Year ROIIC % is 103.39 as of Dec. 2025, which is at its 10-year median of 103.39. GuruFocus rates HKSE:02563 with a GF Score™ of 9/100. The stock has 4 warning signs investors should review. Among 1,312 Biotechnology companies, Beijing Biostar Pharmaceuticals Co ranks better than 78.89% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Beijing Biostar Pharmaceuticals Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 103.39%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Beijing Biostar Pharmaceuticals Co 3-Year ROIIC % Related Terms
Beijing Biostar Pharmaceuticals Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Biostar Pharmaceuticals Co 3-Year ROIIC % Chart
Beijing Biostar Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
3-Year ROIIC %
0.00
0.00
0.00
103.39
Beijing Biostar Pharmaceuticals Co Semi-Annual Data
HKSE:02563 vs VRTX, REGN, MRNA: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Beijing Biostar Pharmaceuticals Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Biostar Pharmaceuticals Co 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Biostar Pharmaceuticals Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Beijing Biostar Pharmaceuticals Co's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -128.778 (Dec. 2025) - -223.497 (Dec. 2022) )
/
( 280.532 (Dec. 2025) - 188.917 (Dec. 2022) )
=
94.719
/
91.615
=
103.39%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a 3-Year ROIIC % of 103.39 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. This is near median its historical median of 103.39. Over the past decade, Beijing Biostar Pharmaceuticals Co's 3-Year ROIIC % has ranged from 103.39 to 103.39. According to the industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #277 out of 1312 companies in the Biotechnology industry, placing it in the top 21.1%.
Is Beijing Biostar Pharmaceuticals Co's 3-Year ROIIC % too high?
Beijing Biostar Pharmaceuticals Co's current 3-Year ROIIC % of 103.39 is near median its 10-year median of 103.39. Over the past 10 years, this metric has ranged from a low of 103.39 to a high of 103.39. Based on the distribution chart, Beijing Biostar Pharmaceuticals Co ranks #277 out of 1312 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #277 out of 1312 companies for 3-Year ROIIC %. This places Beijing Biostar Pharmaceuticals Co in the top 21% of its industry — outperforming the majority of peers. Historically, Beijing Biostar Pharmaceuticals Co's own 3-Year ROIIC % has ranged from 103.39 to 103.39 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. Beijing Biostar Pharmaceuticals Co's current 3-Year ROIIC % is 103.39, which is near median its own 10-year median of 103.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current 3-Year ROIIC % of 103.39. The current 3-Year ROIIC % is 103.39, which is near median its 10-year median of 103.39. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current 3-Year ROIIC % is 103.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score
Get the complete analysis for HKSE:02563
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02563 has been successfully added to your 
